natgillin/translations-raw huggingface dataset:
Det blokerer et stof, der hedder trombin, som spiller en central rolle i blodkoaguleringsprocessen.
It blocks a substance called thrombin, which is central to the process of blood clotting.
Det blokerer for de enzymer i CMV, der hedder ’DNA-polymeraser’, som virussen bruger til at danne DNA.
It blocks the activity of enzymes called ‘DNA polymerases’ in CMV, which the virus uses to produce DNA.
Det blokerer for enzymet topoisomerase I, som cellerne skal bruge til at kopiere dna som en forudsætning for at lave nye celler.
It blocks an enzyme called topoisomerase I, which is involved in copying cell DNA, which is needed to make new cells.
Det blokerer proteasomsystemet, som er et system i cellerne, der regulerer visse proteiner, og som er nødvendigt for cellernes overlevelse.
It blocks the proteasome system, which is a system within the cells that regulates certain proteins and is necessary for the cell to survive.
Det blokerer proteinet CCR5 på overfladen af cellerne hos den hiv-smittede patient.
It blocks a protein called CCR5, which is found on the surface of the cells in the body that HIV infects.
Det blokerer receptorerne for et kemisk signalstof i kroppen kaldet interleukin1.
It blocks the receptors for a chemical messenger in the body called interleukin 1.
Det blokerer virkningen af enzymerne Src- og Bcr-Abl-tyrosinkinase, der findes i receptorer på overfladen af leukæmiceller, hvor de medvirker til at stimulere cellerne til at dele sig ukontrolleret.
It blocks the action of certain enzymes known as Src and Bcr-Abl tyrosine kinases, which can be found in some receptors on the surface of leukaemia cells where they are involved in stimulating the cells to divide uncontrollably.
Det blå håndtag skal være lukket.
Keep the blue handle closed
Det bruges hos voksne, når metformin ikke er egnet til behandling af type 2-diabetes mellitus (ikke- insulinkrævende).
It is used in adults when metformin is not suitable to treat type 2 (non-insulin dependent) diabetes mellitus.
Det bruges også til patienter, som har oplevet alvorlige bivirkninger med tidligere behandling og ikke kan fortsætte med den.
It is also used in patients who experienced serious side effects with previous treatment and are not able to continue taking it.
Det bruges sammen med et andet lægemiddel mod kræft, der hedder vemurafenib.
It is used in combination with another anti-cancer medicine called vemurafenib.
Det bruges som et lysaktiveret lægemiddel (fotosensibiliserende stof).
It is used as a light- activated medicinal product (photosensitiser).
Det bruges som varig behandling til at lindre symptomerne på kronisk obstruktiv lungesygdom (KOL) hos voksne.
It is used as a maintenance (regular) treatment to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Det bruges som varig behandling til at lindre symptomerne på kronisk obstruktiv lungesygdom (KOL) hos voksne.
It is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Det bruges til at behandle Cushings sygdom hos voksne patienter, hvor operation ikke er mulig, eller hvor operationen mislykkedes.
It is used to treat Cushing’s disease in adult patients for whom surgery is not an option or for whom surgery has failed.
Det bruges til behandling af irritabel tyktarm (IBS) med diaré (IBS-D) hos voksne.
It is used to treat irritable bowel syndrome (‘IBS’) with diarrhoea (IBS-D) in adults.
Det bruges til behandling af patienter (voksne og børn over 2 år) med: invasiv aspergillose (en infektion forårsaget af Aspergillus-arter) infektion i blodet af Candida-arter (candidæmi) hos patienter, der ikke har et lavt antal hvide blodlegemer alvorlige invasive infektioner med Candida-arter, når svampen er resistent over for fluconazol (et andet middel mod svampeinfektion) alvorlige svampeinfektioner forårsaget af Scedosporium- eller Fusarium-arter (to andre typer svamp).
It is used for the treatment of patients (adults and children over the age of 2) with: invasive aspergillosis (a type of fungal infection due to Aspergillus sp), candidaemia (another type of fungal infection due to Candida sp) in non-neutropenic patients (patients without abnormally low white blood cells count), serious invasive Candida sp.infections when the fungus is resistant to fluconazole (another antifungal medicine), serious fungal infections caused by Scedosporium sp.or Fusarium sp. (two different species of fungi).
Det bruges til behandling af patienter (voksne og børn over 2 år) med: invasiv aspergillose (en infektion forårsaget af Aspergillus-arter) infektion i blodet af Candida-arter (candidæmi) hos patienter, der ikke har et lavt antal hvide blodlegemer alvorlige invasive infektioner med Candida-arter, når svampen er resistent over for fluconazol (et andet middel mod svampeinfektion) alvorlige svampeinfektioner, der skyldes Scedosporium sp. eller Fusarium sp. (to forskellige svampearter).
It is used for the treatment of patients (adults and children over the age of 2) with: invasive aspergillosis (a type of fungal infection due to Aspergillus sp.), candidaemia (another type of fungal infection due to Candida sp.) in non-neutropenic patients (patients without abnormally low white blood cell count), serious invasive Candida sp. infections when the fungus is resistant to fluconazole (another antifungal medicine), serious fungal infections caused by Scedosporium sp. or Fusarium sp. (two different species of fungi).
Det bruges til regulering af blodsukkeret hos voksne med type 2-sukkersyge.
It is used in adults with type 2 diabetes to control their blood glucose (sugar) level.
Det bruges til voksne til behandling af følgende betæ ndelsessygdomme:
It is used in adults for the following inflammatory diseases:
Det brugte injektionssystem i den lukkede emballage og batteriet skal herefter bortskaffes i henhold til lokale retningslinjer.
The used administration system in the closed outer package and the battery are then to be disposed of according to local requirements.
Det brugte injektionssystem i den tillukkede ydre emballage og batteriet skal bortskaffes i henhold til lokale retningslinjer.
The used administration system in the closed outer package and the battery are then to be disposed of according to local requirements.
Det bør
Dose adjustment for
Det bør administreres ved brug af sterile engangskanyler til pen.
It has to be administered using sterile, disposable pen needles.
Det bør anvendes med forsigtighed hos AKS-patienter:
It should be used with caution in ACS patients:
Det bør bemæ rkes, at der i størstedelen af disse tilfæ lde var tale om tuberkulose med ekstrapulmonal placering i form af enten lokal eller dissemineret sygdom.
It should be noted that in the majority of these reports tuberculosis was extrapulmonary, presenting as either local or disseminated disease.
Det bør bemærkes at faldet i suppression af virus-RNA sås hyppigere, når behandling med indinavir blev initieret ved lavere doser end den anbefalede orale dosis på 2,4 g/dag.
It should be noted that the decrease in suppression of viral RNA levels was seen more frequently when therapy with indinavir was initiated at doses lower than the recommended oral dose of
Det bør bemærkes, at daratumumab bundet til erytrocytter kan maskere påvisning af antistoffer mod ubetydelige (minor) antigener i patientens serum.
It should be recognised that daratumumab bound to RBCs may mask detection of antibodies to minor antigens in the patient’s serum.
Det bør bemærkes, at der hurtigt opnåedes større hæmatologisk respons (MaHR) (de fleste inden for 35 dage efter første administration af dasatinib til patienter med CML i lymfoid blastfase, og inden for 55 dage for patienter med Ph+ ALL).
Of note, major haematologic responses (MaHR) were achieved quickly (most within 35 days of first dasatinib administration for patients with lymphoid blast CML, and within 55 days for patients with Ph+ ALL).
Det bør bemærkes, at systemisk eksponering til voksne hanrotter var lavere end terapeutisk eksponering til mennesker ved 40 mg.
It should be noted that systemic exposure in adult male rats was lower than the therapeutic exposure in humans at 40 mg.
Det bør blandes med 5 ml blød mad eller væske, og denne suspension tages gennem munden.
They should be mixed with 5 ml of soft food or liquid to make a suspension to be taken by mouth.
Det bør blive siddende i 4 timer og dernæst fjernes.
It should be left for 4 hours, and then be removed.
Det bør der tages hensyn til ved tolkning af knoglebilledresultaterne.
This should be considered when interpreting bone- imaging results.
Det bør der tages hensyn til, når toptecan ordineres hvis det f.eks. overvejes at behandle patienter med øget risiko for tumorblødning.
This should be taken into account when prescribing topotecan, e.g. in case patients at increased risk of tumour bleeds are considered for therapy.
Det bør derfor ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af hereditær lactasemangel (Lapp Lactase Deficiency) eller glucose/galactosemalabsorption.
Consequently, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.
Det bør derfor overvejes at give de to vacciner med mindst 4 ugers mellemrum.
Therefore consider administration of the two vaccines separated by at least 4 weeks.
Det bør derfor undgås at Collier, Old English Sheepdogs og beslægtede racer eller krydsninger indtager præparatet oralt.
Oral uptake by Collies, Old English Sheepdogs and related breeds or crossbreeds should thus be avoided.
Det bør derfor undgås til patienter med sjælden arvelig mangel på hypoxantin-guanin-fosforibosyltransferase (HGPRT) såsom Lesch-Nyhan og Kelley-Seegmiller syndrom.
Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl- transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
Det bør derfor undgås til patienter med sjældne arvelig mangel på hypoxantin-guanin-fosforibosyltransferase (HGPRT) såsom Lesch-Nyhan og Kelley-Seegmiller syndrom.
Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl- transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
Det bør desuden ikke anvendes hos patienter, som har haft kræft eller har aktiv tuberkulose, andre alvorlige infektioner, andre former for psoriasis eller svækket immunfor- svar.
It should also not be used in patients who have had cancer, who have active tuberculosis or another severe infection, who have other types of psoriasis, or who have low levels of immunity.
Det bør dog bemærkes, at der blandt en samlet gruppe på 810 patienter – herunder patienter uden malignitet – som behandledes med bexaroten, forekom tre alvorlige bivirkninger med dødelig udgang (akut pankreatitis, subduralt hæmatom og leversvigt).
However, among a total of 810 patients, including those without malignancy, treated with bexarotene, there were three serious adverse reactions with fatal outcome (acute pancreatitis, subdural haematoma and liver failure).
Det bør erindres, at
It should be kept in
Det bør for disse patienter overvejes at fordoble tiden til fjernelse af katetret, mindst 24 timer for den laveste ordinerede enoxaparindosis (30 mg en gang dagligt) og mindst 48 timer for den højeste dosis (1 mg/kg legemsvægt dagligt).
In these patients one should consider doubling the timing of removal of a catheter, at least 24 hours for the lower prescribed dose of enoxaparin (30 mg once daily) and at least 48 hours for the higher dose (1 mg/kg bw/day).
Det bør foretrækkes at administrere ikke- adjuverede sæsoninfluenza-vacciner før eller sammen med første dosis Pandemrix.
It is preferable that non-adjuvanted seasonal influenza vaccines should be administered before or with the first dose of Pandemrix.
Det bør heller ikke anvendes hos kvinder med auramigræne (visuelle eller andre symptomer), visse kræftformer eller blødning fra underlivet, som ikke er blevet diagnosticeret.
It should not be used in women who have migraine with aura (visual or other symptoms), some types of cancer or abnormal bleeding from the genital area whose cause has not been diagnosed.
Det bør heller ikke anvendes hos patienter med porfyri (manglende evne til at nedbryde en type kemiske stoffer, der kaldes porfyriner) eller til patienter med visse hudsygdomme af forskellig oprindelse, der skyldes udsættelse for lys.
It must not be used in people who have porphyria (an inability to break down chemicals called porphyrins) or people who have certain skin diseases of different origins caused by exposure to light.
Det bør ikke administreres i en indgang som indeholder glucose.
It should not be administered in a line containing dextrose.
Det bør ikke anvendes til at behandle kvalme og opkastning efter kemoterapi.
It should not be used to treat nausea and vomiting following chemotherapy.
Det bør ikke anvendes til gravide kvinder.
It should not be used in pregnant women.
Det bør ikke erstatte eller erstattes af andre paclitaxelformuleringer.
It should not be substituted for or with other paclitaxel formulations.
Det bør imidlertid anføres, at systemisk eksponering hos gnavere var den samme eller lavere end terapeutisk eksponering hos mennesker ved doser på 125 mg/80 mg og 165 mg.
However, it should be noted that systemic exposure in rodents was similar or even lower than therapeutic exposure in humans at the 125 mg/80 mg and 165 mg doses.
Det bør imidlertid bemærkes, at patienterne i denne undersøgelse modtog højere doser end den anbefalede dosis (op til 10 mg to gange dagligt).
However it should be noted that patients in this study were given doses higher than the recommended dose (up to 10 mg twice a day).
Det bør indtages to gange dagligt med vand, om morgenen og om aftenen, delt i to lige store doser.
It should be taken twice daily with water in the morning and in the evening, in two equally divided doses.
Det bør indtages to gange dagligt, om morgenen og om aftenen, delt i to lige store doser.
It should be taken twice daily in the morning and in the evening, in two equally divided doses.
Det bør kun anvendes efter nøje overvejelse af andre behandlingsmuligheder.
It should be used after careful evaluation of alternative treatment options.
Det bør kun anvendes, når andre lægemidler ikke er egnede.
It should only be used when other medicines are unsuitable.
Det bør kun ordineres til patienter, der er over 12 år og er fastslået at have F508del-mutationerne i begge kopier af CFTR-genet.
It should be prescribed only to patients aged 12 years and above confirmed to have the F508del mutation in both copies of the CFTR gene.
Det bør også overvejes at afbryde behandlingen med Stribild i tilfælde af progressiv forværring af nyrefunktionen, når der ikke er identificeret andre årsager.
Interrupting treatment with Stribild should also be considered in case of progressive decline of renal function when no other cause has been identified.
Det bør også overvejes at afbryde behandlingen med tenofovirdisoproxilfumarat hos voksne patienter med kreatininclearance på < 50 ml/min eller fald i serumphosphat til < 1,0 mg/dl (0,32 mmol/l).
Consideration should also be given to interrupting treatment with tenofovir disoproxil fumarate in adult patients with creatinine clearance decreased to < 50 ml/min or decreases in serum phosphate to < 1.0 mg/dl (0.32 mmol/l).
Det bør også overvejes at afbryde behandlingen med tenofovirdisoproxilfumarat i tilfælde af progressiv forværring af nyrefunktionen, når der ikke er identificeret andre årsager.
Interrupting treatment with tenofovir disoproxil fumarate should also be considered in case of progressive decline of renal function when no other cause has been identified.
Det bør også overvejes at afbryde behandlingen med Viread i tilfælde af progressiv forværring af nyrefunktionen, når der ikke er identificeret andre årsager.
Interrupting treatment with Viread should also be considered in case of progressive decline of renal function when no other cause has been identified.
Det bør overvejes at afbryde behandlingen med eller seponere pomalidomid i tilfælde af grad 2-3 hududslæt.
Pomalidomide interruption or discontinuation should be considered for Grade 2-3 skin rash.
Det bør overvejes at afbryde behandlingen med Emtricitabine/Tenofovir disoproxil Zentiva hos patienter, hvor kreatinin-clearance falder til < 50 ml/min eller serumphosphat til < 1,0 mg/dl (0,32 mmol/l).
Consideration should be given to interrupting treatment with Emtricitabine/Tenofovir disoproxil Zentiva in patients with creatinine clearance decreased to < 50 ml/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/l).
Det bør overvejes at afbryde Flixabi- behandlingen, hvis disse forstyrrelser fortsæ tter.
Discontinuation of Flixabi should be considered if these disorders develop.
Det bør overvejes at afbryde Inflectra-behandlingen, hvis disse sygdomme udvikles.
Discontinuation of Inflectra should be considered if these disorders develop.
Det bør overvejes at afbryde Remsima-behandlingen, hvis disse sygdomme udvikles.
Discontinuation of Remsima should be considered if these disorders develop.
Det bør overvejes at anvende korttidsvirkende antacida i stedet for PPI’er, og bosutinib og antacida skal om muligt administreres på separate tidspunkter (f.eks. kan bosutinib tages om morgenen og antacida om aftenen).
Short-acting antacids should be considered as an alternative to PPIs and administration times of bosutinib and antacids should be separated (i.e. take bosutinib in the morning and antacids in the evening) whenever possible.
Det bør overvejes at begrænse den maksimale dosis af Lojuxta i henhold til den tilsigtede LDL-C- respons.
Consider limiting the maximum dose of Lojuxta according to desired LDL-C response.
Det bør overvejes at forlænge behandlingsvarigheden på over 12 uger og op til 24 uger, især for de undergrupper, der har en eller flere faktorer, der historisk er forbundet med lavere responsrater for interferon-baserede behandlinger (f.eks. fremskreden fibrose/cirrose, høje virale koncentrationer ved baseline, sort race, IL28B non CC-genotype, tidligere nul-respons til peginterferon alfa og ribavirinbehandling).
Consideration should be given to potentially extending the duration of therapy beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower response rates to interferon-based therapies (e.g. advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype, prior null response to peginterferon alfa and ribavirin therapy).
Det bør overvejes at forsinke indgiften af Rapiscan, indtil blodtrykket er under kontrol.
Consideration should be given to delaying Rapiscan administration until blood pressure is well controlled
Det bør overvejes at give disse patienter en lavere startdosis (5 mg).
A lower starting dose (5 mg) should be considered for such patients.
Det bør overvejes at give intermitterende behandling eller at nedsætte filgrastimdosis hos patienter, som udvikler trombocytopeni dvs. hos patienter, som får et vedvarende trombocyttal på < 100.000/mm3.
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm3 .
Det bør overvejes at henvise patienter med nyopstået eller forværring af tegn og symptomer der typder på PML til neurologisk undersøgelse på en klinik, der er udstyret til at diagnosticere PML.
Any patients with new onset or worsening signs and symptoms suggestive of PML should be considered for neurological referral at a center equipped to diagnose PML.
Det bør overvejes at indstille behandlingen midlertidigt eller nedsætte dosis af filgrastim hos patienter, der får trombocytopeni, dvs. trombocyttal vedvarende < 100.000/mm3.
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm3.
Det bør overvejes at intensivere kortikosteroidbehandlingen.
Consideration should be given to increasing corticosteroid therapy.
Det bør overvejes at nedsætte pramipexoldosis i tilfælde, hvor disse lægemidler administreres samtidigt med Oprymea.
Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly.
Det bør overvejes at pausere behandlingen, nedsætte dosis eller seponere behandlingen, hvis nævnte symptomer opstår.
Dosing interruption, dose reduction, or discontinuation should be considered as appropriate if such symptoms are observed.
Det bør overvejes at redosere og titrere rekombinant faktor VIIa afhængigt af responset på behandlingen af blødningen.
Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.
Det bør overvejes at reducere dosis af glukokortikoidet samtidig med tæt monitorering af lokale og systemiske bivirkninger eller at skifte til et glukokortikoid, som ikke er et substrat for CYP3A4 (f.eks. beclomethason).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (eg, beclomethasone).
Det bør overvejes at seponere bisphosphonat hos patienter med mistanke om atypisk femurfraktur, indtil der foreligger en evaluering af patienten, baseret på en individuel benefit/risk- vurdering.
Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.
Det bør overvejes at seponere Brintellix hos patienter med symptomatisk hyponatriæmi og iværksætte passende intervention.
Discontinuation of Brintellix should be considered in patients with symptomatic hyponatraemia and appropriate medical intervention should be instituted.
Det bør overvejes at seponere det samtidigt administrerede lægemiddel midlertidigt i de 6 dage, som behandlingen med tedizolidphosphat varer, hvis det er muligt.
If possible, an intermission of the co-administered medicinal product should be considered during the six days of treatment with tedizolid phosphate.
Det bør overvejes at seponere lægemidlet, hvis flere end to doser forsinkes på grund af toksicitet relateret til behandlingen i de første 48 uger.
Discontinuing the product should be considered if there are more than 2 dose delays due to toxicities related to the treatment during the first 48 weeks.
Det bør overvejes at seponere Prolia hos patienter, hvor der er mistanke om en atypisk femurfraktur, mens en evaluering af patienten baseret på individuel vurdering af fordele kontra risici afventes.
Discontinuation of Prolia therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient based on an individual benefit risk assessment.
Det bør overvejes at seponere XGEVA hos patienter, hvor der er mistanke om en atypisk femurfraktur, mens patienten evalueres på basis af en individuel vurdering af fordele kontra risici.
Discontinuation of XGEVA therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient based on an individual benefit risk assessment.
Det bør overvejes at tilføje dækning med systemisk kortikosteroid i stressperioder eller i forbindelse med operation.
Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Det bør overvejes at titrere dosis mellem 500 μg, 300 μg og 150 μg.
Appropriate dose titration between 500 μg, 300 μg, and 150 μg should be considered.
Det bør overvejes at udføre knoglemarvsaspiration og - biopsi i løbet af sygdommen og behandlingen – især hos patienter over 60 år samt hos patienter med systemiske symptomer og unormale tegn.
Consideration should be given to performing a bone marrow aspirate and biopsy over the course of the disease and treatment, particularly in patients over 60 years of age, those with systemic symptoms or abnormal signs.